MA10.01 Antibiotic Use and PD-1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.395
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.07-008 Microbiome & Immunotherapy: Antibiotic Use Is Associated With Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

Immune Reprogramming via PD-1 Inhibition Enhances Early-Stage Lung Cancer Survival

JCI insight
Medicine
2018English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immunotherapies Based on PD-1/PD-L1 Pathway Inhibitors in Ovarian Cancer Treatment

Clinical and Experimental Immunology
AllergyImmunology
2019English

Doses of Aminophylline Given Intravenously in Casualty.

BMJ
1984English

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature

Cancer
Cancer ResearchOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy